Once-daily integrase inhibitor (INSTI) with boosted darunavir
is non-inferior to standard of care in virologically suppressed
children, Week 48 results of the SMILE PENTA-17 TRIAL; presented at IAS 2021 – the 11th IAS Conference on HIV Science|18-21 JULY 2021
A. Compagnucci , M. Chan, Y. Saïdi, T. Cressey, A. Bamford, Y.
Riault, A. Coelho, A. Nolan, S. Chalermpantmetagul, P. Amuge, V.
Musiime, A. Violari, M. Cotton, S. Kanjanavanit, A. Volokha, R. Bologna,
N. Pavia Ruz, L. Tato Prieto, P. Paioni, L. Marques, V. Reliquet, S.
Welch, D. Ford, C. Giaquinto, D. Gibb, A. Babiker, J.T. Ramos Amador,
and the SMILE-PENTA 17 Trial Group. Abstract
Neuropsychiatric manifestations and sleep disturbances in
children and adolescents randomised to dolutegravir-based ART vs
standard-of-care in the ODYSSEY trial; presented at IAS 2021 – the 11th IAS Conference on HIV Science|18-21 JULY 2021
A.
Turkova , A. Kekitiinwa, E. White, V. Mumbiro, E. Khauda, A. Liberty,
E. Dobbels, G.M. Ahimbisibwe, T. Moloantoa, L. Atwine, S. Kanjanavanit,
N.R. Mosia, T. Puthanakit, T. Smit, R. Kobbe, C. Fortuny, E. Chidziva,
R.C. Kyambadde, D. Bbuye, T. Sarfati , A. Coelho, Y. Saïdi , A. Lugemwa ,
N. Klein, M. Bwakura- Dangarembizi, C. Kityo, M. Cotton, C. Giaquinto,
P. Rojo, D.M Gibb, D. Ford, the ODYSSEY trial team. Abstract
Weight gain in children and adolescents on dolutegravir vs standard of care in the ODYSSEY trial; presented at IAS 2021 – the 11th IAS Conference on HIV Science|18-21 JULY 2021
A.
Turkova, C. Kityo, H.A Mujuru, E. Variava , A. Kekitiinwa, A. Lugemwa,
L. Barlow-Mosha, C. Ngampiyaskul, P. Zuidewind, T. Puthanakit, R.
Mngqbisa, N.O. Behuhuma, H. Kataike, G. Musoro, A. Nandudu, P. Amuge, S.
Makumbi, S. Danaviah, S. Ali, B. Wynne, Y. Riault, S. Welch, T.R
Cressey, A. Violari, A. Compagnucci, J. Hakim, P. Rojo, C. Giaquinto,
D.M Gibb, D. Ford, the ODYSSEY trial team. Abstract
Effect of dolutegravir on folate and vitamin B12 status among HIV-infected children and adolescents in the ODYSSEY trial; presented at IAS 2021 – the 11th IAS Conference on HIV Science|18-21 JULY 2021
L.
Barlow-Mosha *, G. Ahimbisibwe, E. Chappell, P.M. Amuge, A. Nanduudu,
E. Kaudha, T. Amukele, D. Balamusani, B. Kafufu, A. Nimwesiga, C. Kityo,
A.R Kekitiinwa, R. Namwanje, G. Kasangaki, A. Mulindwa, G.A. Muzorah,
D. Bbuye, M. Nolan, C. Giaquinto, D.M Gibb, D. Ford, P. Musoke, A.
Turkova, The ODYSSEY Trial Team. Abstract
Virological failures and genotypic resistance in children and
adolescents randomised to dolutegravir-based ART vs. standard-of-care
in the ODYSSEY trial; presented at IAS 2021 – the 11th IAS Conference on HIV Science|18-21 JULY 2021
C.
Kityo *, E. White, A. Turkova, H.A Mujuru, I. Nankya, B. Wynne, S. Ali,
A. Kekitiinwa, A. Lugemwa, E. Kaudha, A. Liberty, H. Cassim, M.
Archary, M. Cotton, L. Barlow-Mosha, T.R Cressey, C. Ngampiyasakul , U.
Srirompotong, O. Behuhuma, Y. Saidi, A. Bamford, R. Kobbe, P. Rojo, C.
Giaquinto, D. Gibb, D. Ford. Abstract
A randomised comparison of DTG-based ART vs standard of care
in infants and young children living with HIV weighing 3 to 14kg:
results from the ODYSSEY trial; presented at IAS 2021 – the 11th IAS Conference on HIV Science|18-21 JULY 2021
A.
Lugemwa *, H. Mujuru, B. Wynne, A. Violari, A. Kekitiinwa, C. Kityo, M.
Archary, E. Variava , T. Sarfati, C. Shakeshaft, R. Turner, K. Nathoo,
E. Chidziva, L. Atwine, N. Ramsagar, A. Liberty , P. Amuge, E. Kaudha,
A. Nanduudu, R. Mngqibisa, R. Mosia, M. Cotton, T. Cressey, T.
Puthanakit, A. Compagnucci, C. Giaquinto, P. Rojo, D. Ford, D.M Gibb, A.
Turkova, ODYSSEY trial team. Abstract
OPTIPRIM 2-ANRS 169 TRIAL COMPARING DOLUTEGRAVIR VS DARUNAVIR IN ACUTE HIV-1 INFECTION; presented at IAS 2021 – the 11th IAS Conference on HIV Science|18-21 JULY 2021
Authors
: Antoine Chéret, Rebecca Bauer, Vincent Meiffrédy, Pauline Lopez,
Elise Gardiennet, Faïza Ajana, Karine Lacombe, Philippe Morlat, Caroline
Lascoux, Jacques Reynes, Gilles Pialoux, Cécile Goujard, Christine
Rouzioux , Véronique Avettand-Fenoel, Laurence Meyer.
Anal, oral and genital distribution of HPV in PrEP-users MSM:
results at baseline of the ANRS IPERGAY HPV sub-study. 22nd
International AIDS conference, Amsterdam, the Netherlands 2018, Abstract
TUPEB056.
Laurent Cotte, David
Veyer, Isabelle Charreau, Jean Francois Fléjou, Hélène Péré, Eric Cua,
Julie Chas, Isabelle Heard, Constance Delaugerre, Catherine Capitant,
Jean-Michel Molina and ANRS IPERGAY Study group.
Is Prevalence of Early HIV-Infection at Baseline Correlated
with HIV Incidence: An analysis of 10 PrEP trials. 22nd International
AIDS conference, Amsterdam, the Netherlands 2018, Abstract WEPEC 318.
Antoni G, Pintado C, Delaugerre C, Meyer L, Molina JM.
In Depth Sampling of High Risk Populations to Characterize HIV
Transmission Epidemics among Young MSM using PrEP in France and Quebec
A. Chaillon, C. Delaugerre, N. Mahjoub, B. Brenner, C. Capitant, D.
Carette, M.L. Nere, G.Pialoux, E. Cua, L. Cotte, C. Tremblay, B. Spire,
M. Wainberg, C. Goujard, L. Meyer, J.M. Molina, M.L. Chaix
Attitudes about PrEP among physicians who participated in the
Open-Label Extension of the ANRS-IPERGAY trial: a qualitative study.
Marion Di Ciaccio, Marie Suzan-Monti, Christian Chidiac, Camille
Bernaud, Antoine Cheret, Gilles Pialoux, Eric Cua, Marine Saouzanet,
Emmanuelle Netzer, Bruno Spire, Jean Michel Molina, Marie Préau
Impact of risk perception trajectory on PrEP and condom use
among Men who have Sex with Men during the Open-Label-Extension of the
ANRS-IPERGAY trial.
Marion Di
Ciaccio, Luis Sagaon-Teyssier, Marie Suzan-Monti, Bakridine
Mmadi-mrenda, Eric Cua, Gilles Pialoux, Nicolas Leturque, Valérie
Foubert, Marie Préau, Jean Michel Molina, Bruno Spire
Low T cell immunogenicity of the yellow fever vaccine in HIV-infected patients: ANRS EP46 NOVAA
Authors:
A. Samri, C. Durier, N. Colin de Verdiere, V. Meiffredy, O. Launay, S.
Matheron, S. Mercier-Delarue, A. Boulay, J.-P. Aboulker, J.-M. Molina,
F. Simon, B. Autran
First report after early termination of ANRS COV1-COHVAC cohort of healthy volunteers from preventive HIV-1 vaccine trials
Authors:
C. Desaint, C. Durier, J.-D. Lelièvre, B. Silbermann, G. Pialoux, L.
Cuzin, I. Poizot-Martin, P. Morineau, Z. Sumer-Yalcin, C. Lascoux, A.
Bouakane, A. Diallo, J.-P. Aboulker, B. Spire, L. Meyer, O. Launay,
COHVAC Study Group, ANRS and Vaccine Research Institute (VRI)